Cargando…

Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology

BACKGROUND: Duchenne muscular dystrophy (DMD) is a fatal muscle‐wasting disorder caused by genetic loss of dystrophin protein. Extracellular microRNAs (ex‐miRNAs) are putative, minimally invasive biomarkers of DMD. Specific ex‐miRNAs (e.g. miR‐1, miR‐133a, miR‐206, and miR‐483) are highly up‐regulat...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Westering, Tirsa L.E., Lomonosova, Yulia, Coenen‐Stass, Anna M.L., Betts, Corinne A., Bhomra, Amarjit, Hulsker, Margriet, Clark, Lucy E., McClorey, Graham, Aartsma‐Rus, Annemieke, van Putten, Maaike, Wood, Matthew J.A., Roberts, Thomas C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113513/ https://www.ncbi.nlm.nih.gov/pubmed/31849191 http://dx.doi.org/10.1002/jcsm.12506

Ejemplares similares

Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties
por: Chwalenia, Katarzyna, et al.
Publicado: (2022)

The Effects of Low Levels of Dystrophin on Mouse Muscle Function and Pathology
por: van Putten, Maaike, et al.
Publicado: (2012)

A dystrophic Duchenne mouse model for testing human antisense oligonucleotides
por: Veltrop, Marcel, et al.
Publicado: (2018)

Dystrophin involvement in peripheral circadian SRF signalling
por: Betts, Corinne A, et al.
Publicado: (2021)

Good news for the mdx mouse community: Improved dystrophin restoration after skipping mouse dystrophin exon 23
por: Aartsma-Rus, Annemieke
Publicado: (2022)

Influence of full-length dystrophin on brain volumes in mouse models of Duchenne muscular dystrophy
por: Kogelman, Bauke, et al.
Publicado: (2018)

The use of genetically humanized animal models for personalized medicine approaches
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2019)

Sensitive and reliable evaluation of single-cut sgRNAs to restore dystrophin by a GFP-reporter assay
por: Lyu, Pin, et al.
Publicado: (2020)

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
por: Tanganyika-de Winter, Christa L, et al.
Publicado: (2012)

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
por: van Putten, Maaike, et al.
Publicado: (2014)

Multiomic characterization of disease progression in mice lacking dystrophin
por: Signorelli, Mirko, et al.
Publicado: (2023)

Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse model
por: Marchal, Gerard A., et al.
Publicado: (2021)

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment
por: Betts, Corinne A, et al.
Publicado: (2019)

Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD
por: Hanson, Britt, et al.
Publicado: (2022)

Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice
por: Betts, Corinne A., et al.
Publicado: (2015)

Autophagy is Impaired in the Tibialis Anterior of Dystrophin Null Mice
por: Spitali, Pietro, et al.
Publicado: (2013)

Voltage-Dependent Sarcolemmal Ion Channel Abnormalities in the Dystrophin-Deficient Heart
por: Koenig, Xaver, et al.
Publicado: (2018)

Moving neuromuscular disorders research forward: from novel models to clinical studies
por: van Putten, Maaike, et al.
Publicado: (2020)

Nonclinical Exon Skipping Studies with 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn−/− Mice Inspired by Clinical Trial Results
por: van Putten, Maaike, et al.
Publicado: (2019)

Assessment of Behavioral Characteristics With Procedures of Minimal Human Interference in the mdx Mouse Model for Duchenne Muscular Dystrophy
por: Engelbeen, Sarah, et al.
Publicado: (2021)

Dystrophin deficiency leads to dysfunctional glutamate clearance in iPSC derived astrocytes
por: Patel, Abdulsamie M., et al.
Publicado: (2019)

Non-sequential and multi-step splicing of the dystrophin transcript
por: Gazzoli, Isabella, et al.
Publicado: (2015)

Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy
por: Doorenweerd, Nathalie, et al.
Publicado: (2017)

Loss of sarcolemmal dystrophin and dystroglycan may be a potential mechanism for myocardial dysfunction in severe sepsis
por: Celes, MRN, et al.
Publicado: (2009)

Author Correction: Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy
por: Doorenweerd, Nathalie, et al.
Publicado: (2018)

Disruption of sarcolemmal dystrophin and β-dystroglycan may be a potential mechanism for myocardial dysfunction in severe sepsis
por: Celes, MR, et al.
Publicado: (2010)

Dystrophin R16/17-syntrophin PDZ fusion protein restores sarcolemmal nNOSμ
por: Patel, Aman, et al.
Publicado: (2018)

Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
por: Kemaladewi, Dwi U, et al.
Publicado: (2011)

Mutation-independent Proteomic Signatures of Pathological Progression in Murine Models of Duchenne Muscular Dystrophy
por: van Westering, Tirsa L. E., et al.
Publicado: (2020)

Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice
por: Walter, Lisa M, et al.
Publicado: (2018)

Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy
por: van Putten, Maaike, et al.
Publicado: (2019)

Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle
por: Morin, Adrien, et al.
Publicado: (2023)

GRAF1 deficiency blunts sarcolemmal injury repair and exacerbates cardiac and skeletal muscle pathology in dystrophin-deficient mice
por: Lenhart, Kaitlin C., et al.
Publicado: (2015)

Dystrophin R16/17 protein therapy restores sarcolemmal nNOS in trans and improves muscle perfusion and function
por: Zhao, Junling, et al.
Publicado: (2019)

Pharmacological activation of SERCA ameliorates dystrophic phenotypes in dystrophin-deficient mdx mice
por: Nogami, Ken'ichiro, et al.
Publicado: (2021)

Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration
por: Roberts, Thomas C., et al.
Publicado: (2015)

Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2019)

A modified diet does not ameliorate muscle pathology in a mouse model for Duchenne muscular dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2019)

Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy
por: Malerba, Alberto, et al.
Publicado: (2012)

Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics
por: McClorey, Graham, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_16jdmduvobkec2jsd28kt6q1qa